UNC data indicates that treatment of stem cells with cosalane prior to transplantation greatly reduces the incidence of aGVHD, while preserving the GVL effect in several transplant models. Our recent studies demonstrated that knock-out of the cc-chemokine receptor 7 (CCR7), by cosalane, in murine T cells impaired their ability to induce aGVHD. Significantly, these T cells retained their graft-versus-leukemia (GVL) response in mouse stem cell transplant models.
-CCR7 inhibition reduces incidence of graft-versus-host disease
-Cosalane-treated T cells retain graft-versus-leukemia responses
Inventors: James Coghill and Kenneth Fowler
- The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models Biol Blood Marrow Transplant. 2019 Jun;25(6):1062-1074